Catheter Precision, Inc. (VTAK)
About Catheter Precision, Inc.
Catheter Precision Inc is engaged in the design, manufacture, and sale of medical technologies focused in the field of cardiac electrophysiology, or EP. The company's two primary products include the VIVO System and LockeT. The VIVO System, which is an acronym for View into Ventricular Onset System(VIVO or VIVO System), is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its newest product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $819.0K
- Net income
- -$17.2M
- Total assets
- $15.9M
- Market cap
- $2.8M
- Gross margin
- 92.3%
- Operating margin
- -2581.6%
- Net margin
- -2160.6%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $819.0K
- Cost of revenue
- $63.0K
- Gross profit
- $756.0K
- Operating expenses
- $21.9M
- Operating income
- -$21.1M
- Income tax
- -$1.8M
- Net income
- -$17.7M
- EPS (basic)
- $-15.90
Balance sheet
- Total assets
- $15.9M
- Current assets
- $390.0K
- Total liabilities
- $9.2M
- Current liabilities
- $3.9M
- Shareholders’ equity
- $6.7M
Cash flow
- Operating cash flow
- -$8.3M
- Investing cash flow
- $167.0K
- Financing cash flow
- $5.3M
- Net cash flow
- -$2.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $2.8M
- Shares outstanding
- 10.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 27, 2018
Catheter Precision, Inc. (VTAK) Stock Price
- Reported a net loss of $17.2M in FY2025.
- Revenue grew 85% from FY2023 to FY2025.
- Gross margin of 92.3%, net margin -2160.6%.
- Trading 95% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Catheter Precision, Inc..
Write a review
News about Catheter Precision, Inc.
News & sentiment via Polygon.io
Catheter Precision, Inc.: frequently asked questions
Is Catheter Precision, Inc. an American company?
Catheter Precision, Inc. is a US-based company headquartered in Fort Mill, South Carolina, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Catheter Precision, Inc. headquartered?
Catheter Precision, Inc. is headquartered in Fort Mill, South Carolina, United States.
Is Catheter Precision, Inc. publicly traded?
Yes — Catheter Precision, Inc. is a publicly traded company. Its stock trades under the ticker symbol VTAK on the NYSE.
What does Catheter Precision, Inc. do?
Catheter Precision, Inc. is an American Medical Devices company in the Health & Beauty sector.
